New drug KP-001 put to the heart test in healthy volunteers
NCT ID NCT06649942
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This study checks whether KP-001, an experimental drug, affects the heart's electrical activity (QT interval) in 40 healthy adults. Participants receive single doses of KP-001, a placebo, or moxifloxacin (a control) in random order. The goal is to ensure KP-001 does not cause dangerous heart rhythm changes before moving to larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS - MALE AND FEMALE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Parexel Early Phase Clinical Unit - Los Angeles
Glendale, California, 91206, United States
Conditions
Explore the condition pages connected to this study.